Treatment

Literature ordered by Tumor

• Treatment Options for Glioblastoma

Overviews

• Treatment Overviews
• Evaluations and Comparisons

Surgery

• Surgery of Low Grade Gliomas
• Surgery of Metastatic Tumors
• Surgery of Pediatric Patients
• Surgical Neuro-Oncology

Radiation

• Brachytherapy
• Radiation-Enhancing Agents
• Radioimmunotherapy
• Radiosurgery
• Radiotherapy

Chemotherapy

• Busulfan
• Bleomycin
• Capecitabine (Xeloda)
• Carboplatin (CBDCA)
• Carmustine (BCNU)
• Chemotherapy Overviews
• Chemotherapy-Enhancing Agents
• Chemotherapy Timing
• Cisplatin (CDDP)
• Cloretazine
• Cyclophosphamide
• Cytarabine (Ara-C)
• Dacarbazine
• Docetaxel (Taxotere)
• Doxorubicin (Caelyx)
• Etoposide (VP-16)
• Fluorouracil
• Gemcitabine
• Hydroxyurea
• Ifosfamide
• Irinotecan (CPT-11)

• Lomustine (CCNU)
• Marimastat
• Melphalan
• Methotrexate
• Methylprednisolone
• Nimustine (ACNU)
• Oxaliplatin
• Paclitaxel (Taxol)
• PCV (Procarbazine, Lomustine, and Vincristine)
• Procarbazine (PCB)
• Pyrazoloacridine
• Ranimustine (MCNU)
• Temozolomide Clinical Investigations
• Temozolomide Laboratory Investigations
• Teniposide (VM26)
• Thiotepa
• Topotecan and Camptothecin analogues
• VCP (Vincristine, Lomustine, and Prednisone)
• Vinblastine
• Vincristine
• Vinorelbine

Treatment Agents

• AEE788 (HER+VEGFR inhibitor)
• Antibodies
• Bevacizumab (Avastin)
• Bortezomib (Velcade)
• Cabergoline
• Dexamethasone and Steroids
• Desferoxamine (DFO)
• EGFR inhibitors (Cetuximab, ect.)
• mTOR inhibitors
• Fenofibrate (a.o. anti-hypercholesterolemia agents)
• Flavopiridol (inhibitor of cyclin dep. kinases)
• Fluvastatin
• Gefitinib (ZD1839, Iressa)

• Imatinib (Gleevec, STI571)
• Kinase Inhibitors
• Nonsteroidal Anti-Inflamm.Drugs (Celebrex, etc.)
• OSI-774 (Erlotinib, Tarceva)
• Phelynbutyrate
• Rapamycin (Rapamune, Sirolimus)
• Retinoids (Isotretinoin, Fenretinide, etc.)
• Rituximab
• Tamoxifen
• Thalidomide (Thalomid, Lenalidomide,...)
• Trastuzumab
• YM155 (Survivin suppressant)

Topics

• Anticonvulsants
• Antiangiogenesis
• Antisense Therapy
• Bioreductive Antitumor Agents
• C5R Protocol
• Cancer Stem Cells
• Cyclooxygenase
• Electric Fields
• Hedgehog Pathway Inhibitors
• Immunotherapy

• Individualised Therapy
• Inhibition of Cell Signalling Channels
• Interferon
• Monoclonal Antibodies
• Nerve Growth Factor
• Signaling Pathway Inhibitors
• Somatostatin
• Stem-Cell-based Therapy
• Targeted Therapy
• Tumor Reversion

Tumor/Treatment Related Pathology

• Anticonvulsant Pathology
• Blood Diseases and Disorders
• Brain Inflammation
• Cardiological Diseases
• Chemoresistance
• Collateral damage in nontargeted tissues
• Chemotherapy Related Phatology
• Diarrhea
• Edema
• Effects on Liver
• Endocrine Morbidity
• Failure to diagnose
• Fatal Outcome
• Fatigue
• Gastric Damage
• Headache
• Hydrocephalus
• Induced Second Neoplasm
• Infections
• Leptomeningeal Diseases
• Long Term Complications
• Malnutrition

• Miscellany (Hemorrhagic cystitis, etc.)
• Multifocal Tumor Recurrences
• Neoplastic Fever
• Neoplastic Meningitis
• Neurologic Complications
• Cancer Pain
• Obesity
• Paraneoplastic Neurological Disorders
• Plateau Waves
• Pneumonia
• Pseudoprogression
• Radiation Related Pathology
• Radionecrosis
• Radioresistance
• Malignization and Recurrence
• Secondary Adrenal Insufficiency
• Seizures
• Spinal Cord  Compression
• Spondilodiscitis
• Surgery Related Pathology
• Thromboembolism
• Transplant